Biomarkers In The Diagnosis Of Irritable Bowel Syndrome, What Is The Reality?

Abstract

The way to correct diagnosis in the Irritable bowel syndrome (IBS) in the most of cases is long and requires the number of laboratory and instrumental examinations. The diversity of the pathophysiology of IBS and heterogeneity within the syndrome nosology, including genetic predisposition, psychological aspects, visceral hypersensitivity, disorders of gastrointestinal motility, changes in the neuroendocrine system (brain-gut axis), low-grade inflammation, imbalance of microbiota, etc. dictate the necessity of developing a workable routine tests for rapid and efficient verification of IBS. Considering IBS as a diagnosis of exclusion, we are on a path that requires a clear pharmacological justification and, therefore, in most Western countries remains unacceptable. Therefore, the search for biomarkers of IBS is actual. Current publication describes current data available on this subject. Among them are the data of studies on the diagnostic value of markers of inflammation in patients with IBS, elevated levels of stress agents in biological environments, and the development of special diagnostic panels of biomarkers, allowing to exclude a wide range of the diseases that have similar presentations to IBS.